Julia Kaiser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia Kaiser has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Gerd Fastner
Department of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria
3 shared publications - Brane Grambozov
Department of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria
2 shared publications - Christoph Fussl
Department of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria
2 shared publications - Christoph Gaisberger
Department of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria
2 shared publications - Felix Sedlmayer
Department of Radiation Oncology, Paracelsus Medical University, SALK, A-5020 Salzburg, Austria
2 shared publications - Franz Zehentmayr
Department of Radiation Oncology, Paracelsus Medical University, A-5020 Salzburg, Austria
2 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3664
A 3D CBCT-Based Approach to Assessing Effective Radiation Penetration Depth in Intraoperative Electron Radiotherapy
Background/Objectives: Accurate characterization of treatment geometry is essential for intraoperative electron radiotherapy (IOeRT) treatment planning. Mobile cone-beam computed tomography (CBCT) enables volumetric assessment of intraoperative anatomy beyond conventional point-based measurements. This study compared clinically applied distance measurement techniques with geometric distance descriptors retrospectively extracted from comprehensive three-dimensional CBCT datasets. Methods: Ninety-six patients receiving IOeRT as a tumor-bed boost during breast-conserving surgery were included. Manual CBCT measurements (mCBCT) were compared with mean (USavg) and minimum (USmin) ultrasound measurements per patient. Comprehensive 3D distance extraction was performed in 82 CBCT datasets using an approximated thoracic-wall surface as the geometric reference. Minimum and first-quartile distances were evaluated across the complete applicator cross-section and within a 1-cm-diameter inner disk around the central beam axis. Results: The mean paired difference between mCBCT and USavg was 0.3 mm and was not statistically significant, whereas mCBCT measurements exceeded USmin by an average of 1.5 mm. In the principal comparison, the minimum CBCT-derived distance within the inner disk was 1.4 mm smaller than mCBCT. Across the complete applicator area, minimum distances were 9.1-10.7 mm smaller than the clinical measurements. The first-quartile distance across all surface points was 1.4 mm smaller than mCBCT, whereas the corresponding inner-disk difference was not statistically significant after correction. Isodose-atlas-based dose-volume analysis indicated that a 1.5-mm change in assumed penetration depth could correspond to an approximately 7% change in the 90% isodose volume at shallow depths. Conclusions: Clinical CBCT and ultrasound measurements showed small group-level differences but substantial patient-level variability. Comprehensive 3D CBCT analysis revealed spatial variations in tissue depth not fully represented by the clinical measurements, highlighting the limitations of characterizing treatment geometry using a single distance. Although anatomical accuracy and patient-specific dosimetric consequences remain to be established, these findings support the potential of intraoperative 3D CBCT to advance IOeRT toward individualized, image-guided treatment planning.
- 5 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3664
Open AccessA 3D CBCT-Based Approach to Assessing Effective Radiation Penetration Depth in Intraoperative Electron Radiotherapy
Background/Objectives: Accurate characterization of treatment geometry is essential for intraoperative electron radiotherapy (IOeRT) treatment planning. Mobile cone-beam computed tomography (CBCT) enables volumetric assessment of intraoperative anatomy beyond conventional point-based measurements. This study compared clinically applied distance measurement techniques with geometric distance descriptors retrospectively extracted from comprehensive three-dimensional CBCT datasets. Methods: Ninety-six patients receiving IOeRT as a tumor-bed boost during breast-conserving surgery were included. Manual CBCT measurements (mCBCT) were compared with mean (USavg) and minimum (USmin) ultrasound measurements per patient. Comprehensive 3D distance extraction was performed in 82 CBCT datasets using an approximated thoracic-wall surface as the geometric reference. Minimum and first-quartile distances were evaluated across the complete applicator cross-section and within a 1-cm-diameter inner disk around the central beam axis. Results: The mean paired difference between mCBCT and USavg was 0.3 mm and was not statistically significant, whereas mCBCT measurements exceeded USmin by an average of 1.5 mm. In the principal comparison, the minimum CBCT-derived distance within the inner disk was 1.4 mm smaller than mCBCT. Across the complete applicator area, minimum distances were 9.1-10.7 mm smaller than the clinical measurements. The first-quartile distance across all surface points was 1.4 mm smaller than mCBCT, whereas the corresponding inner-disk difference was not statistically significant after correction. Isodose-atlas-based dose-volume analysis indicated that a 1.5-mm change in assumed penetration depth could correspond to an approximately 7% change in the 90% isodose volume at shallow depths. Conclusions: Clinical CBCT and ultrasound measurements showed small group-level differences but substantial patient-level variability. Comprehensive 3D CBCT analysis revealed spatial variations in tissue depth not fully represented by the clinical measurements, highlighting the limitations of characterizing treatment geometry using a single distance. Although anatomical accuracy and patient-specific dosimetric consequences remain to be established, these findings support the potential of intraoperative 3D CBCT to advance IOeRT toward individualized, image-guided treatment planning.
- Open Access
- 13 May 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 1835-1846
Re-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis
The treatment of locally recurrent lung cancer is a major challenge for radiation-oncologists, especially with data on high-dose reirradiation being limited to small retrospective studies. The aim of the present study is to assess overall survival (OS) for patients with locally recurrent lung cancer after high-dose thoracic reirradiation. Thirty-nine patients who were re-irradiated for lung cancer relapse between October 2013 and February 2019 were eligible for the current retrospective analysis. All patients were re-irradiated with curative intent for in-field tumor recurrence. The diagnostic work-up included a mandatory 18F-FDG-PET-CT scan and—if possible—histological verification. The ECOG was ≤2, and the interval between initial and second radiation was at least nine months. Thirty patients (77%) had non-small cell lung cancer (NSCLC), eight (20%) had small cell lung cancer (SCLC), and in one patient (3%) histological confirmation could not be obtained. More than half of the patients (20/39, 51%) received re-treatment with dose differentiated accelerated re-irradiation (DART) at a median interval of 20.5 months (range: 6–145.3 months) after the initial radiation course. A cumulative EQD2 of 131 Gy (range: 77–211 Gy) in a median PTV of 46 mL (range: 4–541 mL) was delivered. Patients with SCLC had a 3 mL larger median re-irradiation volume (48 mL, range: 9–541) compared to NSCLC patients (45 mL, range: 4–239). The median cumulative EQD2 delivered in SCLC patients was 84 Gy (range: 77–193 Gy), while NSCLC patients received a median cumulative EQD2 of 135 Gy (range: 98–211 Gy). The median OS was 18.4 months (range: 0.6–64 months), with tumor volume being the only predictor (p < 0.000; HR 1.007; 95%-CI: 1.003–1.012). In terms of toxicity, 17.9% acute and 2.6% late side effects were observed, with a toxicity grade >3 occurring in only one patient. Thoracic high dose reirradiation plays a significant role in prolonging survival, especially in patients with small tumor volume at recurrence.
- 13 May 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 1835-1846
Open AccessRe-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis
The treatment of locally recurrent lung cancer is a major challenge for radiation-oncologists, especially with data on high-dose reirradiation being limited to small retrospective studies. The aim of the present study is to assess overall survival (OS) for patients with locally recurrent lung cancer after high-dose thoracic reirradiation. Thirty-nine patients who were re-irradiated for lung cancer relapse between October 2013 and February 2019 were eligible for the current retrospective analysis. All patients were re-irradiated with curative intent for in-field tumor recurrence. The diagnostic work-up included a mandatory 18F-FDG-PET-CT scan and—if possible—histological verification. The ECOG was ≤2, and the interval between initial and second radiation was at least nine months. Thirty patients (77%) had non-small cell lung cancer (NSCLC), eight (20%) had small cell lung cancer (SCLC), and in one patient (3%) histological confirmation could not be obtained. More than half of the patients (20/39, 51%) received re-treatment with dose differentiated accelerated re-irradiation (DART) at a median interval of 20.5 months (range: 6–145.3 months) after the initial radiation course. A cumulative EQD2 of 131 Gy (range: 77–211 Gy) in a median PTV of 46 mL (range: 4–541 mL) was delivered. Patients with SCLC had a 3 mL larger median re-irradiation volume (48 mL, range: 9–541) compared to NSCLC patients (45 mL, range: 4–239). The median cumulative EQD2 delivered in SCLC patients was 84 Gy (range: 77–193 Gy), while NSCLC patients received a median cumulative EQD2 of 135 Gy (range: 98–211 Gy). The median OS was 18.4 months (range: 0.6–64 months), with tumor volume being the only predictor (p < 0.000; HR 1.007; 95%-CI: 1.003–1.012). In terms of toxicity, 17.9% acute and 2.6% late side effects were observed, with a toxicity grade >3 occurring in only one patient. Thoracic high dose reirradiation plays a significant role in prolonging survival, especially in patients with small tumor volume at recurrence.
- Open Access
- 19 January 2017
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 1-7
Intraoperative radiotherapy (IORT) as boost in breast cancer
The term IORT (intraoperative radiotherapy) is currently used for various techniques that show huge differences in dose delivery and coverage of the tissue at risk. The largest evidence for boost IORT preceding whole breast irradiation (WBI) originates from intraoperative electron treatments (IOERT) with single doses around 10 Gy. At median follow-up periods at 6 years, outstandingly low local recurrence rates of less than 1% are observed. Higher local relapse rates were described for G3 tumors and triple negative breast cancers as well as for IORT following primary systemic treatment for locally advanced tumors. Even there, long term (>5y) local tumor control rates mostly beyond 95% were maintained. Compared to other boost methods, an intraoperative treatment has evident advantages in terms of precision (by avoiding a “spatial and/or temporal miss”), cosmetic outcome and patient comfort. Direct visualisation of a tumor bed during surgery guarantees for an accurate dose delivery, which has additionally gained importance in times of primary reconstruction techniques after lumpectomy, since IORT is performed before breast tissue including parts of the tumor bed is mobilized for plastic purposes. As a consequence of direct tissue exposure without distension by hematoma/seroma, IORT allows for small treatment volumes and complete skin sparing, both having a positive effect on late tissue tolerance and, hence, cosmetic appearance. Boost IORT marginally prolongs the surgical procedure, while significantly shortening postoperative radiotherapy. Its combination with external beam radiotherapy to the whole breast (WBI) is currently tested in two multicentric prospective trials: as kV-IORT in the multicentric TARGIT-B (oost) study, and as IOERT in the HIOB trial (3 weeks hypofractionated WBI preceded by IORT electron boost).
- 19 January 2017
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 1-7
Open AccessIntraoperative radiotherapy (IORT) as boost in breast cancer
The term IORT (intraoperative radiotherapy) is currently used for various techniques that show huge differences in dose delivery and coverage of the tissue at risk. The largest evidence for boost IORT preceding whole breast irradiation (WBI) originates from intraoperative electron treatments (IOERT) with single doses around 10 Gy. At median follow-up periods at 6 years, outstandingly low local recurrence rates of less than 1% are observed. Higher local relapse rates were described for G3 tumors and triple negative breast cancers as well as for IORT following primary systemic treatment for locally advanced tumors. Even there, long term (>5y) local tumor control rates mostly beyond 95% were maintained. Compared to other boost methods, an intraoperative treatment has evident advantages in terms of precision (by avoiding a “spatial and/or temporal miss”), cosmetic outcome and patient comfort. Direct visualisation of a tumor bed during surgery guarantees for an accurate dose delivery, which has additionally gained importance in times of primary reconstruction techniques after lumpectomy, since IORT is performed before breast tissue including parts of the tumor bed is mobilized for plastic purposes. As a consequence of direct tissue exposure without distension by hematoma/seroma, IORT allows for small treatment volumes and complete skin sparing, both having a positive effect on late tissue tolerance and, hence, cosmetic appearance. Boost IORT marginally prolongs the surgical procedure, while significantly shortening postoperative radiotherapy. Its combination with external beam radiotherapy to the whole breast (WBI) is currently tested in two multicentric prospective trials: as kV-IORT in the multicentric TARGIT-B (oost) study, and as IOERT in the HIOB trial (3 weeks hypofractionated WBI preceded by IORT electron boost).